Last $1.94 USD
Change Today -0.01 / -0.51%
Volume 104.6K
CDXS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 1:51 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

codexis inc (CDXS) Snapshot

Open
$1.96
Previous Close
$1.95
Day High
$1.98
Day Low
$1.90
52 Week High
07/15/14 - $2.65
52 Week Low
12/24/13 - $1.24
Market Cap
75.0M
Average Volume 10 Days
505.2K
EPS TTM
$-0.98
Shares Outstanding
38.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CODEXIS INC (CDXS)

codexis inc (CDXS) Related Businessweek News

View More BusinessWeek News

codexis inc (CDXS) Details

Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States, Europe, and Asia. It offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company also provides development services, such as enzyme screening, enzyme optimization, and enzyme services, as well as markets and sells pharmaceutical intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, it develops biocatalysts for use in various fine chemicals market segments, including food, animal feed, polymers, flavors and fragrances, and agricultural chemicals. The company sells its products through its direct sales and business development force. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

125 Employees
Last Reported Date: 03/13/14
Founded in 2002

codexis inc (CDXS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $592.0K
Chief Administrative Officer, General Counsel...
Total Annual Compensation: $334.8K
Special Advisor
Total Annual Compensation: $68.8K
Compensation as of Fiscal Year 2013.

codexis inc (CDXS) Key Developments

Codexis, Inc. Announces Executive Changes Effective August 18, 2014

The Board of Directors of Codexis, Inc. has appointed Gordon Sangster as the company's Senior Vice President and Chief Financial Officer, such appointment to be effective August 18, 2014. Mr. Sangster will replace David McCaman as the company's principal financial officer and principal accounting officer effective as of that date. Mr. Sangster, age 61, joins the company from Nitinol Devices & Components, a private medical device manufacturer, where he served as Chief Financial Officer from October 2011 until July 2014. Prior to that role, Mr. Sangster was Chief Financial Officer of ITC Nexus-Dx.

Codexis, Inc. - Special Call

To discuss the strategic collaboration and license agreement with GSK

Codexis Signs Platform Technology License Agreement with GlaxoSmithKline

Codexis, Inc. announced that it has signed a platform technology license agreement with GlaxoSmithKline plc. Under the terms of the agreement, Codexis granted GlaxoSmithKline a license to use its proprietary CodeEvolver protein engineering platform technology in the field of human healthcare. The license allows GlaxoSmithKline to use Codexis' platform technology to develop novel enzymes for use in the manufacture of its pharmaceutical and health care products. GlaxoSmithKline may also use the licensed technology to develop new therapeutic, diagnostic and prophylactic products in the human health field. Upon completion of technology transfer, GlaxoSmithKline will have Codexis' CodeEvolver protein engineering platform installed at its Upper Merion, Pennsylvania research and development site. Codexis is eligible to receive up to $25 million over approximately the next two years, $6 million of which will be paid upfront shortly after signing and an additional $19 million subject to satisfactory completion of technology transfer milestones. Codexis also has the potential to receive numerous additional milestone payments that range from $5.75 million to $38.5 million per project based on GlaxoSmithKline's successful application of the licensed technology. In addition, Codexis will be eligible to receive royalties based on net sales, if any, of a limited set of products developed by GSK using Codexis' CodeEvolver protein engineering platform technology.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDXS:US $1.94 USD -0.01

CDXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cambrex Corp $21.83 USD -0.067
Koninklijke DSM NV €51.94 EUR -0.59
Novozymes A/S kr280.30 DKK -0.60
Takasago International Corp ¥492.00 JPY 0.00
View Industry Companies
 

Industry Analysis

CDXS

Industry Average

Valuation CDXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.7x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CODEXIS INC, please visit www.codexis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.